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Brucellosis is an important zoonotic disease of nearly worldwide distribution. Despite the availability of live
vaccine strains for bovine (S19, RB51) and small ruminants (Rev-1), these vaccines have several drawbacks,
including residual virulence for animals and humans. Safe and efficacious immunization systems are therefore
needed to overcome these disadvantages. A vjbR knockout was generated in the S19 vaccine and investigated for its
potential use as an improved vaccine candidate. Vaccination with a sustained-release vehicle to enhance vaccination
efficacy was evaluated utilizing the live S19 vjbR::Kan in encapsulated alginate microspheres containing a non-
immunogenic eggshell precursor protein of the parasite Fasciola hepatica (vitelline protein B). BALB/c mice were
immunized intraperitoneally with either encapsulated or nonencapsulated S19vjbR::Kan at a dose of 1 105 CFU
per animal to evaluate immunogenicity, safety, and protective efficacy. Humoral responses postvaccination indicate
that the vaccine candidate was able to elicit an anti-Brucella-specific immunoglobulin G response even when the
vaccine was administered in an encapsulated format. The safety was revealed by the absence of splenomegaly in
mice that were inoculated with the mutant. Finally, a single dose with the encapsulated mutant conferred higher
levels of protection compared to the nonencapsulated vaccine. These results suggest that S19 vjbR::Kan is safer
than S19, induces protection in mice, and should be considered as a vaccine candidate when administered in a
sustained-release manner.
Brucella abortus, a gram-negative, facultative, intracellular
bacterium, is a causative agent of brucellosis, a zoonosis of
nearly worldwide distribution (5). In animals, brucellosis is a
major cause of abortions and infertility (3, 19, 28). In humans,
infection can cause a serious debilitating disease manifested as
undulant fever, endocarditis, arthritis, and osteomyelitis (23).
Due to serious economic losses and public health risk, exten-
sive efforts have been conducted to prevent the disease in
animals through vaccination programs (22). Live attenuated
vaccines have been developed and successfully used worldwide
against bovine brucellosis (26). Currently, no effective vaccines
are available for the prevention of human brucellosis.
B. abortus S19 live vaccine has been extensively used to prevent
bovine brucellosis (22). The S19 vaccine strain was first isolated
from the milk of a Jersey cow in 1923 and, while stored in the
laboratory at room temperature, developed an attenuated phe-
notype (22). Numerous efficacy studies conducted with cattle for
this vaccine have demonstrated that 70% of the vaccinated cattle
are protected from a wild-type exposure (22). The effectiveness
depended on a series of variables, including the age of the vacci-
nated animal, the prevalence of the disease in vaccinated herds,
and the dose and route of the vaccination (22, 26). Although S19
typically exhibits low virulence in cattle, the vaccine can cause
abortions when administered to pregnant animals at rates be-
tween 1 to 2.5% (26). A less-frequent adverse effect of S19 vac-
cination is the development of an arthropathy associated with
Brucella antigen-containing immune complexes (22, 26).
In many developing nations, immunizations derived from
the S19 vaccine have been evaluated in humans. In the former
Soviet Union, the administration of live S19 preparations were
immunogenic, and protection was achieved and considered to
last 1 year but caused a modest but notable incidence of clinical
cases, as well as a hypersensitivity reaction (6, 22). As such, S19
is not a safe vaccine candidate for human use.
Previous research in our lab has identified Brucella genes re-
quired for virulence and survival via transposon mutagenesis (2,
13). Among these, vjbR (BMEI1116), encoding the luxR-like quo-
rum sensing-related transcriptional regulator is required for virB
expression, virulence in mice, and survival in macrophages (8).
BALB/c mice immunized with the vjbR mutant were protected
against wild-type challenge without exhibiting any local or adverse
reactions, making such mutants ideal vaccine candidates for fu-
ture consideration (4). In the present study, the effects of elimi-
nating the vjbR gene from B. abortus S19 were evaluated in vitro
and in BALB/c mice. When vjbR is deleted in S19, two positive
effects are observed: diminished inflammation (reduced spleno-
megaly) and reduced persistence. Taken together, these effects
lead to an increased safety of the vaccine strain, since S19 alone
elicits splenomegaly, an undesirable side effect of vaccination.
The capacity of the B. abortus S19 vjbR::Kan mutant to elicit
Brucella-specific immune responses was also evaluated. In an ef-
fort to enhance the vaccination efficacy, the knockout was encap-
sulated into alginate microspheres containing a nonimmunogenic
eggshell precursor protein of the parasite Fasciola hepatica
(vitelline protein B [VpB]) as previously described (4) that has
been used to alter the release properties of the microcapsules
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with the aim of producing vaccines that are safer while retaining
protective efficacy.
MATERIALS AND METHODS
Mice. One hundred fifty 8- to 10-week-old female BALB/c mice were obtained
from the Jackson Laboratory (Bar Harbor, ME). All experimental procedures
and animal care were performed in compliance with institutional animal care
regulations.
Bacterial strains. Bacterial strains used in these experiments include B. abor-
tus S19 (NVSL, Ames, IA), B. abortus S19 vjbR::Kan (engineered for this
study), and B. abortus virulent strain 2308 (originally obtained from Billy Deyoe).
The bacteria were routinely grown on tryptic soy agar (TSA) at 37°C with 5%
(vol/vol) CO2. For B. abortus S19 vjbR::Kan, the medium was supplemented
with kanamycin (100 g/ml). Following 3 days of incubation, the bacteria were
harvested from the surface of the plates into phosphate-buffered saline (PBS).
The bacteria were pelleted, washed twice by resuspension in MOPS (morpho-
linepropanesulfonic acid) buffer (10 mM MOPS, 0.85% NaCl [pH 7.4]), and
resuspended to a final concentration of 1  106 CFU/ml (for encapsulation) or
1 105 CFU in 100 l of PBS (for nonencapsulated bacteria) based upon optical
density readings using a Klett meter and a standardized curve. The actual viable
counts were confirmed by serial dilution and plating of portions onto TSA plates
with or without antibiotic. To inoculate the mice, the bacteria were harvested the
same day of challenge. Inoculum doses were plated retrospectively to determine
the number of organisms inoculated.
Escherichia coli cultures utilized during the knockout construction were grown
on Luria-Bertani (Difco, Becton Dickinson) plates or in broth overnight at 37°C
with or without kanamycin (100 mg/liter), carbenicillin (100 mg/liter), or chlor-
amphenicol (50 mg/liter).
Construction of the S19 vjbR::Kan deletion mutant. The marked S19
vjbR::Kan deletion mutant was constructed in S19 as previously described with
some modifications (15). Specifically for this mutant, the sequence downstream
of the vjbR gene was amplified from B. abortus 2308 with the primer pair
5-GTCTTCGAGGATGTACAATTGGC and 5-CATCTCGTCTGATCAAC
ATGG. The sequence upstream of vjbR was amplified with the primer pair
5-GAAGCGCCAAAGTATCGC and 5-CAGTTGGAAAAGGGCTTTTCCA
ACCG. These two products were ligated to one another via overlapping PCR
with an AscI site (New England Biolabs) engineered between the two sequences.
This product was then ligated to pEX18Ap, and a kanamycin resistance gene was
inserted within the vector at the unique AscI site. This construct was used for the
electroporation into S19 as previously described (15). Potential marked deletion
mutants were kanamycin resistant and ampicillin sensitive and were verified by
PCR and Southern blotting. The S19 vjbR::Kan mutant was then used for this
study.
Evaluation of B. abortus S19 vjbR::Kan in J774A.1 macrophages. Murine
macrophage-like J774.A1 (ATCC TIB-67) macrophages were used to assess S19
vjbR::Kan mutant survival compared to that of the parental B. abortus S19.
Macrophage survival assays were performed as previously described with some
modifications (24). Briefly, macrophages were cultured in Dulbecco’s modified
Eagle’s medium with 10% (vol/vol) fetal bovine serum, 1 mM L-glutamine, and
1 mM nonessential amino acids. Monolayers of macrophages containing 2.5 
105 cells per well were infected at a multiplicity of infection (MOI) of 1:100 at
37°C with S19 vjbR::Kan, S19, or wild-type 2308. Thirty minutes postinfection,
the cells were washed twice with medium without antibiotics and then incubated
with 50 g/ml of gentamicin (Invitrogen) for 30 min to kill any extracellular
bacteria. One and 48 h postinfection, the macrophages were lysed using 0.05%
(vol/vol) Tween 20 and bacteria collected. Brucella entry and survival were
determined by performing serial dilutions and plating onto TSA plates with or
without antibiotic for each dilution. All assays were performed in triplicate and
repeated at least three times.
Evaluation of B. abortus S19 vjbR::Kan attenuation in mice. Female BALB/c
mice were used to evaluate the survival of the S19 vjbR::Kan mutant. Briefly, 8-
to 10-week-old mice were intraperitoneally (i.p.) inoculated with a total of 1 
106 CFU of either the mutant or parental strain. Groups of five mice were
euthanized via carbon dioxide asphyxiation at 1, 3, 5, 7, or 9 weeks postinocu-
lation. At each time point, the spleens were collected, weighed, and homoge-
nized in 1 ml of peptone saline. Serial dilutions were prepared, and 100-l
aliquots of the different dilutions were plated in duplicate onto TSA or TSA with
kanamycin. The levels of infection were expressed as the mean  standard error
of the mean (SEM) of individual log CFU/spleen.
Histopathology. Twelve 8- to 10-week-old female BALB/c mice were distrib-
uted into groups of three mice and inoculated with 1  105 CFU per mouse of
S19, S19 vjbR::Kan, B. abortus 2308, or PBS. At 3 weeks postinoculation, the
animals were euthanized by CO2 asphyxiation, and the spleens, lungs, livers,
kidneys, and hearts were harvested, fixed in 10% buffered formalin, paraffin
embedded, and stained. Histological changes were assessed between the treat-
ment groups.
Preparation of B. abortus antigen-loaded microspheres. Alginate beads were
prepared as previously described with some modifications (1). Briefly, 6  106
CFU of live B. abortus S19 vjbR::Kan or B. abortus S19 was resuspended in 1 ml
of MOPS buffer (10 mM MOPS, 0.85% NaCl [pH 7.4]) and mixed with 5 ml of
alginate solution (1.5% sodium alginate, 10 mM MOPS, 0.85% NaCl [pH 7.3]).
VpB was added as a component of the alginate core by the addition of 1 mg of
VpB to the bacterium-alginate suspension described above. Spheres were ob-
tained by extruding the suspension through a 200-micron nozzle into a 100 mM
calcium chloride solution and stirring for 15 min using the Inotech encapsulator
I-50 (Inotech Biosystems International, Rockville, MD). After the bacterium-
alginate mixture was extruded into the CaCl2, the capsules were washed twice
with MOPS for 5 min and further cross-linked with 0.05% poly-L-lysine (molec-
ular weight, 22,000; Sigma) for 10 min. Following two successive washes, the
beads were stirred in a solution of 0.03% (wt/vol) alginate for 5 min to apply a
final outer shell and washed twice with MOPS before storage at 4°C. To deter-
mine the bacterial viability postencapsulation, 1 ml of capsules was removed
from the encapsulator prior to permanent cross-linking with poly-L-lysine. The
capsules were allowed to settle and were washed twice with MOPS buffer, and
particles were dissolved using 1 ml of depolymerization solution (50 mM Na3-
citrate, 0.45% NaCl, 10 mM MOPS [pH 7.2]) with stirring for 10 min. The
bacterial number (CFU/ml) in each ml of capsules was determined by plating
onto TSA plates.
Immunization of mice. Twenty 8- to 10-week-old female BALB/c mice were
randomly distributed into groups of five mice for i.p. vaccination. Initial prelim-
inary vaccination studies indicated no difference in vaccination efficacy when
animals were given either 1  105 CFU or 1  106 CFU. The treated animals
were given a single dose of vaccine containing 1  105 CFU of either encapsu-
lated B. abortus S19 vjbR::Kan in alginate with VpB inside the capsule’s shell or
nonecapsulated B. abortus S19 vjbR::Kan. The control groups received 1  105
CFU of either nonencapsulated S19 or empty capsules (no bacteria entrapped)
resuspended in 100 l of MOPS.
Evaluation of Brucella-specific antibody. To determine the effect of encapsu-
lation in the production of anti-Brucella-specific antibody in sera from inoculated
mice, 100 l of blood was taken from each mouse after 0, 3, and 7 weeks
postvaccination as well as 1 week postchallenge. The serum was separated and
used for immunoglobulin G1 (IgG1) and IgG2a determination by enzyme-linked
immunosorbent assay (ELISA). Heat-killed and sonicated B. abortus whole-cell
antigen was used to coat 96-well plates (Nunc-Immuno plates) at a concentration
of 25 g total protein/well. Following overnight incubation at 4°C, the plates
were washed, blocked with 0.5 ml of blocking buffer (0.25% [wt/vol] bovine
serum albumin), and then incubated with mouse sera diluted 1:100 in the same
blocking buffer for 1 h at room temperature. Following the removal of unbound
antibody by extensive washing, goat anti-mouse IgG1 or IgG2a horseradish
peroxidase conjugate (Serotec) was added at a concentration of 500 ng/ml of
antibody and incubation continued for an additional h. Following this incubation,
the plates were washed, horseradish peroxidase substrate was added, and then
the plates were incubated for 18 min. The reaction was stopped by the addition
of 50 l of 0.5 M NaOH and the absorbance measured at 450 nm. All the assays
were performed in triplicate and repeated at least three times.
Efficacy of vaccination. At selected times postvaccination, the mice (n  5 per
group) were challenged i.p. using 1  105 CFU/mouse of B. abortus wild-type
2308. One week postchallenge, the mice were euthanized by CO2 asphyxiation,
and their spleens were removed, weighed, and homogenized in 1 ml of peptone
saline. Serial dilutions were prepared, and 100-l portions were plated onto TSA
plates. In some instances, 200 to 1,000 l of spleen homogenate was plated to
determine organism recovery. To differentiate between the vaccine candidate
and the challenge strain, each dilution was also plated on TSA with kanamycin
to identify any residual kanamycin-resistant vaccine strain present. The levels of
infection were expressed as means  SEMs of the individual log10 CFU/spleen.
The efficacy of the vaccine in the treated animals compared to the nonvaccinated
naïve animals was determined by subtracting the mean CFU/spleen recovered
from the mice vaccinated with the nonencapsulated or encapsulated vaccine
from the mean CFU/spleen recovered from the naïve nonvaccinated but chal-
lenged mice. The efficacy of the encapsulated vaccine compared to that of the
nonencapsulated vaccine was determined by subtracting the mean CFU/spleen
recovered from the mice vaccinated with the capsules from the mean CFU/
spleen recovered from the mice immunized with the nonencapsulated vaccine.
Statistical procedures. Macrophage infection and survival were expressed as
the mean log CFU  standard deviation for each group and analyzed by analysis
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of variance (ANOVA) followed by a Tukey’s posttest comparing all groups to
one another at the same time point. The intensity of infection (bacterial clear-
ance) at each time point was expressed as the mean log CFU  SEM for each
group and analyzed by a two-tailed Student’s t test. The efficacy of the vaccina-
tion and the differences in spleen weight postchallenge were expressed as the
mean log CFU  SEM for each treatment group and analyzed by ANOVA
followed by a Tukey’s posttest comparing all groups to one another. IgG pro-
duction was expressed as the mean absorbance  SEM. The significance of
differences between the groups was determined by ANOVA followed by a
Tukey’s posttest comparing all groups to one another. P values of 0.05 were
considered statistically significant.
RESULTS
B. abortus S19 vjbR::Kan is more attenuated for survival in
macrophages and in mice than S19. To determine the role of
the deletion of the vjbR gene in virulence in S19, J774A.1
macrophages were infected with the marked deletion mutant
and compared to the parental strain and to the wild-type B.
abortus 2308. Using an MOI of 100, the ability of the bacteria
to enter and survive within this cell line was evaluated. At 1 h
postinfection (t  0), there was no difference (P 	 0.05) be-
tween S19, B. abortus 2308, or S19 vjbR::Kan in the number
of bacteria infecting the cell. By 48 h postinfection, there was
a 0.96-log difference (P  0.001) in the number of organisms
infecting the cell for S19 versus that for wild-type 2308 or a
1.47-log difference between the number for S19 vjbR::Kan
versus that for wild-type 2308 (P  0.001). When the marked
mutant was compared to the parental strain (S19), there was a
0.51-log reduction in the number of bacteria surviving inside
the macrophage (P  0.05) (Fig. 1). These results indicate that
S19 vjbR::Kan is attenuated in macrophages.
To determine the virulence of S19 vjbR::Kan in vivo, mice
were inoculated i.p. with 1  106 CFU/mouse of S19
vjbR::Kan or the parental strain S19. Compared to that of
S19, the colonization of S19 vjbR::Kan in the spleen did not
differ (P	 0.05) at 1, 3, 5, or 7 weeks postinfection, and at only
9 weeks postinfection, bacterial colonization of S19 vjbR::Kan
was significantly reduced (P  0.013) compared to that of S19
(Fig. 2A). Interestingly, inflammation in the spleen was dimin-
ished in animals that received S19 vjbR::Kan at the majority
of the time points compared to that in the S19-infected ani-
mals, as was evident by the lack of splenomegaly (Fig. 2B).
Gross morphology was evaluated and again demonstrated the
significant reduction in the spleen sizes of mice receiving the
S19 vjbR::Kan vaccine compared to those of the S19 controls
(Fig. 3). The spleens of the S19 vjbR::Kan-vaccinated mice
appeared similar in size to those of the PBS-treated controls,
whereas the spleens from the S19-vaccinated mice were com-
parable to those of the wild-type-treated mice.
Evaluation of histological changes in mice inoculated with
S19 vjbR::Kan. Due to the significant differences between the
spleen sizes of the animals inoculated with S19 vjbR::Kan and
FIG. 1. Survival of the B. abortus S19 vjbR::Kan mutant in
J774A.1 macrophages. Wild-type strain 2308, S19, and the B. abortus
S19 vjbR::Kan mutant were used to infect J774A.1 macrophages at an
MOI of 1:100. After 30 min of incubation followed by 1 h of treatment
with gentamicin, infected macrophages were further incubated for 0 or
48 h. Treated cells were lysed, serially diluted, and plated on TSA or
TSA-kanamycin plates for CFU determination. The results are repre-
sented as the means of three independent experiments  SEMs. Sta-
tistical differences were analyzed by ANOVA followed by Tukey’s
posttest comparing all groups to one another. , P  0.001 compared
to the 2308 control; #, P  0.05 compared to S19.
FIG. 2. Clearance of B. abortus S19 vjbR::Kan after infection.
BALB/c mice (n  5/time point) were infected with 1 106 CFU/
mouse of wild-type 2308 or S19 vjbR::Kan. At 1, 3, 5, 7, and 9 weeks
postinfection, mice were euthanized and the spleens were assessed for
bacterial colonization (A) and weight (B). Values are the means of the
results for individual mice standard errors of the means. Differences
were determined by two-tailed Student’s t test comparing S19 to the
mutant (*, P  0.05). The solid line in panel A represents the limit of
detection, which is 5 CFU.
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those of the animals inoculated with S19, the mice were inocu-
lated with either S19 vjbR::Kan, S19, B. abortus 2308, or PBS as
a control. Three mice per group were euthanized, and the
spleens, lungs, livers, kidneys, and hearts were extracted, fixed,
and stained to determine the histological changes associated with
inflammation. The most dramatic histologic changes were ob-
served in the livers and spleens of all the infected mice. The livers
of all the mice inoculated with B. abortus wild-type 2308 and two
mice that received S19 had randomly distributed, severe inflam-
matory foci composed primarily of histiocytes and various num-
bers of lymphocytes and neutrophils (Fig. 4A and B). Bordering
the inflammatory foci were degenerating hepatocytes. Diffusely,
the Kupffer cells of these mice were reactive. Hepatic inflamma-
tory foci in either the S19 vjbR::Kan- or PBS-vaccinated mice
were uncommon and again characterized by histiocytes, lympho-
cytes, and rare neutrophils (Fig. 4C and D).
Severe splenic lesions were similar in animals that received
the B. abortus wild-type 2308 and S19 (two out of three mice)
(Fig. 4E and F). The lesions were characterized by markedly
enlarged and coalescing white pulp marginal zones. These
were composed of large numbers of histiocytes with fewer
variably degenerate neutrophils and occasional lymphocytes
and plasma cells. Often, marginal zones extended both into the
red pulp and compressed the follicles as they surrounded cen-
tral arteries. Up to 60% of the organ-size increase in B. abortus
wild-type 2308 and 50% in S19 vaccinates were due to the
marginal zone expansion by the described cellular infiltrate.
Diffusely, moderate lymphoid hyperplasia with secondary lym-
phoid follicle formation containing increased mitotic activity
and a small number of body macrophages capable of being
stained were observed. The changes in the spleens of two of the
animals that received the S19 vjbR::Kan mutant were char-
acterized by minimal lymphoid follicle hyperplasia with sec-
ondary follicle formation (Fig. 4G). The marginal zones were
mildly hyperplastic with a moderate number of histiocytes and
plasma cells and fewer lymphocytes and neutrophils. Moder-
ately increased numbers of plasma cells and megakaryocytes
were in the red pulp in all treatment groups except in animals
that received PBS. No splenic changes were noted in animals
that received the PBS (Fig. 4H), one mouse vaccinated with
S19, and one mouse that received S19 vjbR::Kan.
Multifocal aggregates of mineralization with accompanying
mild fibrosis and small numbers of lymphocytes, histiocytes,
and rare neutrophils were observed in the epicardial surfaces
of almost all of the mice and were interpreted as unassociated
with the inflammatory process (data not shown).
Changes in the lungs were generally unremarkable in all the
animals, with the exception of two animals infected with 2308.
Changes included minimal edema and a mild-to-moderate
perivascular and peribronchiolar cellular infiltrate composed
of lymphocytes, histiocytes, and neutrophils. There were no
changes observed in any of the kidneys in any group (data not
shown).
Evaluation of immune protection provided by S19 vjbR::
Kan. In order to determine the efficacy of the S19 vjbR::Kan
mutant as a vaccine, the level of protection provided by equal
numbers of either S19 vjbR::Kan or S19 was evaluated against
B. abortus wild-type challenge at 20 weeks postvaccination. To
try to enhance the efficacy of the S19 vjbR::Kan mutant, the
strain was also encapsulated into alginate VpB microcapsules
at the same dose. At 21 weeks postvaccination (1 week post-
challenge), there was a statistically significant decrease in the
splenic bacterial loads from the mice vaccinated with S19
vjbR::Kan relative to those of the naïve mice, with a 3.06-log-
unit (P  0.001) reduction for the nonencapsulated mutant.
When administered in a microencapsulated format, the effi-
cacy of the S19 vjbR::Kan vaccine was enhanced by 0.8 log
unit compared to that of the nonencapsulated S19 vjbR::Kan
vaccine (P  0.05 encapsulated to nonencapsulated; P  0.001
naïve to encapsulated) (Fig. 5A). The S19-vaccinated mice
exhibited a 5.02-log-unit (P  0.001) reduction compared to
that of the naïve animals.
Postchallenge safety was increased in the mice vaccinated
with the novel mutant strain, and splenomegaly was signifi-
cantly reduced in the mice vaccinated with either the encap-
sulated or the nonencapsulated S19 vjbR::Kan strain com-
pared to the S19-vaccinated mice postchallenge (P  0.001)
(Fig. 5B). Taken together with the efficacy results, these data
suggest that the encapsulation of this novel vaccine strain is
highly effective, with the improved benefit of diminished
splenomegaly and improved safety pre- and postchallenge.
Encapsulated S19 vjbR::Kan elicited humoral responses
that the nonencapsulated vaccine failed to induce. Serum col-
lected at 0, 3, 7, and 21 weeks postvaccination (1 week post-
challenge) was assayed for the presence of Brucella-specific
IgG1 versus IgG2a antibodies by ELISA. Immunization with
encapsulated S19 vjbR::Kan elicited stronger IgG1 and IgG2a
responses than the nonencapsulated mutant (P  0.01) (Fig.
6A and B). During the vaccination stages, both isotypes were
induced at similar levels (1:1 ratio), but after challenge, a
higher IgG1 (2:1) subtype was seen. In this case, an induction
of higher and sustained antibody levels coincides with in-
creased protection from encapsulated S19 vjbR::Kan.
DISCUSSION
The development of vaccines to control brucellosis has proven
to be a challenge for years. Extensive use of the S19 vaccine has
played an enormous role in reducing the disease in cattle, but it
FIG. 3. Spleen morphology in BALB/c mice vaccinated with S19
vjbR::Kan. Mice were inoculated with 1  105 CFU of either B.
abortus 2308 (A), S19 vjbR::Kan (B), S19 (C), or PBS (D). Animals
were euthanized 3 weeks postinoculation, and spleens were weighed,
harvested, and fixed for histological analysis.
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became clear that this vaccine in its existing form is of limited use
in controlling the disease for humans and in wildlife populations
(7). Years of investigation have led to a better understanding of
Brucella virulence and the correlates of protective immunity so
that vaccines superior to S19 can be developed. The observation
that the highest levels of protection are obtained when the host is
immunized with live vaccines indicates that persistence and vac-
cine viability are key aspects required for an efficacious antibru-
cellosis vaccine (15, 33).
Previous studies in our laboratory have identified genes
related to survival and virulence using transposon-based mu-
tagenesis strategies. Among the genes identified, Brucella
FIG. 4. Histological analysis of livers and spleens from BALB/c mice inoculated with S19, B. abortus 2308, S19 vjbR::Kan, or PBS. In the livers,
random distribution of inflammatory foci in mice vaccinated with either S19 (A) or 2308 (B) was observed (10 magnification; 40 magnification
in the inset). Normal liver appearance was observed in mice inoculated with either S19 vjbR::Kan (C) or PBS (D). Foci of inflammation are
composed primarily of histiocytes. Scale bars in panels A and B, 100 M; inset scale bars, 25 M. In the spleens of mice vaccinated with either
S19 (E) or 2308 (F), the white pulp is coalescing and enlarged, including marginal zones, and the formation of secondary lymphoid follicles is
present (4 magnification). There was minimal enlargement of the marginal zone in the mice vaccinated with either S19 vjbR::Kan (G) or PBS
(H). Scale bars in panels E to H, 200 M.
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melitensis vjbR mutants have been evaluated for survival in
macrophages and the mouse model to confirm attenuation and
immune potential (4). We have previously demonstrated that
B. melitensis vjbR mutants are suitable vaccine candidates due
to their ability to generate protection in BALB/c mice. Also, by
using this mutant, we were able to increase safety by preventing
splenomegaly in inoculated mice, a significant improvement
over current vaccine strains S19 and Rev-1 that induce spleno-
megaly in mice (27). In this study, we generated a marked
deletion mutant in the S19 vaccine strain with the aim of
increasing safety and the possible use of this vaccine in other
populations.
The S19 vjbR::Kan mutant was evaluated for survival and
attenuation in the macrophage and mouse models. As shown
in this study, S19 vjbR::Kan was defective for survival in
macrophages and cleared faster than S19 in BALB/c mice.
During the initial weeks postinoculation in mice, the mutant
and the parental strain did not clear at statistically different
rates until 9 weeks postinfection, when S19 vjbR::Kan was
undetectable (below the level of detection) in spleens. In con-
trast, the S19-inoculated mice had 1.36 log units of recoverable
bacteria remaining at this time. The increased safety of S19
vjbR::Kan was further revealed by the lack of splenomegaly in
inoculated mice. Even at the initial weeks postinoculation (1, 3,
and 5 weeks) when the bacterial loads in the spleens were
similar to those of the S19-vaccinated mice, the mean spleen
weight of the S19 vjbR::Kan-vaccinated mice was decreased
compared to that of the S19-vaccinated mice. A histological
analysis supported this finding by indicating that the animals
that receive the S19 vjbR::Kan mutant did not elicit the de-
gree of inflammatory response observed in the S19-vaccinated
animals. Furthermore, inflammatory changes observed in
other organs, including the liver, were also significantly dimin-
ished with the mutant. This difference in inflammatory re-
sponse exhibited by the S19 vjbR::Kan-vaccinated animals
provides an opportunity to evaluate the use of S19 vjbR::Kan
as an improved vaccine candidate.
In vitro studies using antigen-presenting cells have demon-
strated that microencapsulated antigens are taken up and pro-
cessed differently than nonencapsulated materials (12). Simi-
larly, in vivo data has shown that microencapsulation serves to
modify the uptake, trafficking, and processing of antigens (29).
Additionally, recent reports demonstrate that the persistence
of the vaccine strain in the host is needed for the development
of suitable and long-term immunity (15). Consistent with this,
the S19 vaccine exhibits only modest attenuation, meaning it
survives longer in the host but also produces unwanted side
effects, such as the severe inflammation reported here. To
enhance the immunization efficacy, we investigated the vaccine
potential of S19 vjbR::Kan when delivered in a controlled-
release vehicle. For this purpose, alginate, a polysaccharide
extracted from algae, was used in combination with VpB, de-
rived from the parasite Fasciola hepatica, as the capsular ma-
terial used to entrap the S19 vjbR::Kan mutant (25, 30, 32).
By encapsulating the organism, we attempted to increase its
persistence without causing inflammation.
Protection studies against wild-type challenge with either the
S19 or S19 vjbR::Kan strains protected mice significantly, but
the efficacy of the vaccine was reduced in the nonencapsulated
S19 vjbR::Kan mutant. This indicated that the vjbR gene in
S19 is necessary to induce a complete immunity toward Bru-
cella infections. The reduced efficacy was successfully compen-
sated by delivering the mutant vaccine in a sustained, microen-
capsulated format, corroborating the observation of
persistence as a function of vaccine efficacy. The encapsulation
of live attenuated organisms is an interesting approach to im-
prove immunization efficacy in potential vaccine candidates.
Using alginate-VpB microencapsulation, bacteria are exposed
to mild conditions in which bacterial viability is not compro-
mised; this approach permits the development of live vaccines
in contrast to previously published encapsulation procedures in
which the viability of the bacteria is compromised due to the
extreme conditions (17). It is important to mention that the
microencapsulation of vaccines has been previously docu-
FIG. 5. Immunization efficacy and safety of B. abortus S19
vjbR::Kan vaccine formulations. BALB/c mice were immunized i.p.
with 1  105 of either nonencapsulated or encapsulated S19
vjbR::Kan. Control groups received empty capsules or S19. After 20
weeks, the mice were challenged i.p. with 1  105 CFU wild-type 2308.
At 1 week postchallenge, the mice were euthanized, their spleens
harvested, and the bacterial loads (A) and spleen weights (B) deter-
mined. (A) Values are reported as the mean log10 recovery of the 2308
challenge organism recovered from the spleens. Differences in coloni-
zation between all the groups were determined by ANOVA followed
by a Tukey’s posttest (*, P  0.05; **, P  0.001). (B) Spleen weights
were measured in mg and were compared and analyzed by ANOVA
followed by a Tukey’s posttest comparing all groups to one another (*,
P  0.01; **, P  0.001). For the statistical representation on both
graphs, “a” symbolizes naïve animals, “b” S19-vaccinated animals, “c”
encapsulated S19 vjbR::Kan-vaccinated animals, and “d” nonencap-
sulated S19 vjbR::Kan-vaccinated animals.
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mented as a alternative method to enhance the efficacy of
DNA, protein-based, and killed vaccines, but to our knowl-
edge, a microencapsulated live Brucella vaccine has been de-
scribed only by us (9–11, 14, 16, 18, 20, 21, 31, 34).
The degree of protection (assessed by splenic bacterial bur-
den) conferred by either the encapsulated or nonencapsulated
S19 vjbR::Kan mutant was compared to humoral profiles.
Immunization with encapsulated S19 vjbR::Kan induced
higher IgG1 and IgG2a levels compared to the nonencapsu-
lated S19 vjbR::Kan mutant. The animals that received the
encapsulated vaccine mounted a stronger IgG1 response at 1
week postchallenge.
In this study, a vjbR knockout was successfully generated in
the S19 vaccine and investigated for its potential use as an
improved vaccine candidate. Vaccination with a sustained-re-
lease vehicle to enhance the vaccination efficacy was evaluated
utilizing live S19 vjbR::Kan to immunize BALB/c mice i.p.
with either encapsulated or nonencapsulated S19 vjbR to
evaluate immunogenicity, safety, and protective efficacy. En-
hanced safety was revealed by the absence of splenomegaly in
mice that were inoculated with the mutant. Humoral responses
postvaccination indicate that the vaccine candidate was able to
elicit an anti-Brucella-specific IgG response even when the
vaccine was administered in an encapsulated format. Finally, a
single dose with the encapsulated mutant conferred higher
levels of protection compared to those of the nonencapsulated
vaccine. These results suggest that S19 vjbR is safer than S19,
induces protection in mice, and should be considered as a
vaccine candidate when administered in a sustained-release
manner.
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